• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Impel Pharmaceuticals Inc.

    12/27/23 9:03:07 AM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMPL alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-40353
    Issuer: IMPEL PHARMACEUTICALS INC
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 201 Elliott Ave West, Suite 260
    Seattle WASHINGTON 98119
    Telephone number: (206) 568-1466
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-12-27 By Aravind Menon Hearings Advisor
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IMPL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMPL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Smith Brandon D

      3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/26/23 4:32:40 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vivo Capital Viii, Llc sold $74,131 worth of shares (575,000 units at $0.13) (SEC Form 4)

      4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/19/23 6:00:01 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brookfield Corp /On/

      4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/4/23 9:00:40 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    SEC Filings

    See more
    • SEC Form EFFECT filed by Impel Pharmaceuticals Inc.

      EFFECT - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/16/24 12:15:09 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Impel Pharmaceuticals Inc.

      S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/14/24 5:21:28 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Impel Pharmaceuticals Inc.

      S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/14/24 5:19:30 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Leadership Updates

    Live Leadership Updates

    See more
    • Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

      SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023. "Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals," said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals. "We are delighted to welcome Michael to Impel's leadership team and believe that

      5/10/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors

      SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and operational expertise. The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately. "It is my pleasure to welcome Darren to the Impel Board of Directors," said Adrian Adams, Chairman of the Board and Chief Executiv

      4/12/23 4:01:00 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Financials

    Live finance-specific insights

    See more
    • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

      5/12/23 8:00:00 AM ET
      $IMPL
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

      SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompan

      5/5/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. "We continued to see strong growth in Trudhesa® prescriptions as we moved i

      3/24/23 8:17:18 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen initiated coverage on Impel NeuroPharma with a new price target

      Cowen initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $35.00

      5/18/21 7:57:51 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Impel NeuroPharma with a new price target

      Wedbush initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $21.00

      5/18/21 7:55:03 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Impel NeuroPharma with a new price target

      Guggenheim initiated coverage of Impel NeuroPharma with a rating of Buy and set a new price target of $32.00

      5/18/21 7:55:03 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale

      Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE, Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets.

      12/19/23 11:10:00 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Exploration of Strategic Alternatives

      SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives. As part of this process, the Company plans to consider a wide range of options with a focus on maximizing shareholder value, including a potential sale of assets of the Company, a sale of all of the Company, a merger or other strategic transactions. As the Company explores strategic options, Impel continues to provide full commercial support

      10/5/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

      5/12/23 8:00:00 AM ET
      $IMPL
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

      Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/13/21 2:21:35 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

      Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/7/21 1:04:43 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      12/4/23 5:12:05 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      11/15/23 4:06:46 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      10/6/23 5:10:06 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care